Select Medical stock surges after RBC raises price target

Jefferies has reaffirmed its Buy rating on Sarepta stock, maintaining a price target of $35. This is significant as it reflects confidence in Sarepta's potential for growth and stability in the market, which could attract more investors and positively influence the stock's performance.

UBS has lowered its price target for Manpower's stock to $40 due to a weak outlook, signaling potential challenges ahead for the company. This adjustment reflects concerns about Manpower's performance in the labor market, which could impact investor confidence and the company's future growth. Such changes in stock targets are crucial as they can influence trading decisions and market perceptions.

RBC Capital has raised its price target for Select Medical's stock to $20, citing recent regulatory relief as a key factor. This adjustment reflects growing confidence in the company's future performance and highlights the positive impact of regulatory changes on its operations. Investors may see this as a promising sign for Select Medical's growth potential.

RBC has raised the stock price target for APi Group to $40, reflecting a strong outlook for the company's results. This adjustment indicates confidence in APi Group's performance and growth potential, which is great news for investors looking for promising opportunities in the market.

Guggenheim has reaffirmed its Buy rating on Spyre stock, maintaining a price target of $65. This endorsement is significant as it reflects confidence in Spyre's growth potential and market performance, which could attract more investors and positively influence the stock's trajectory.

Goldman Sachs has raised its gold price target to an impressive $4,900 by the end of 2026, signaling strong confidence in the precious metal's future value. This adjustment reflects the bank's analysis of economic trends and market conditions, suggesting that investors may want to consider gold as a solid investment option in the coming years. Such a significant price forecast could influence market dynamics and investor behavior, making it a noteworthy development in the financial landscape.

Jefferies has started coverage on Legence stock, assigning it a Hold rating with a price target of $34. This move indicates a cautious approach towards the stock, suggesting that while it may not be a strong buy at the moment, it holds potential for stability. Investors should pay attention to this rating as it reflects the analysts' outlook on Legence's performance in the market.

Seaport has upgraded Netflix to a 'Buy' rating and increased its price target ahead of the company's Q3 earnings report. This positive shift reflects confidence in Netflix's growth potential and suggests that investors may see favorable results soon. Such upgrades can influence market sentiment and attract more investors, making it a significant development for the streaming giant.

Pernod Ricard's price target has been lowered to €129 by Bernstein due to ongoing foreign exchange headwinds. This adjustment reflects the challenges the company faces in the current economic climate, which could impact its profitability and investor confidence. Understanding these shifts is crucial for stakeholders as they navigate the complexities of the global market.

Bernstein has raised its price target for RTX to $181, highlighting the company's strong performance in the defense sector. This adjustment reflects confidence in RTX's growth potential, especially as defense spending continues to rise. Investors may see this as a positive indicator of the company's future profitability and stability, making it an attractive option in the current market.

H.C. Wainwright has reaffirmed its Buy rating on SolarBank stock, setting a price target of $6. This endorsement is significant as it reflects confidence in SolarBank's growth potential and market position, which could attract more investors and boost the company's stock performance.

Jefferies has raised its price target for Nanobiotix to EUR 21.00, highlighting the company's broad potential in cancer treatment. This adjustment reflects growing confidence in Nanobiotix's innovative approaches to oncology, which could significantly impact patient care and the market. Investors and stakeholders should take note, as this could signal a promising future for the company and its contributions to cancer therapies.

McCormick & Co. is currently navigating a complex landscape as it implements its volume growth strategy while facing margin pressures. This situation is significant because it highlights the challenges that companies often encounter when trying to expand their market presence without compromising profitability. Investors and stakeholders will be keen to see how McCormick balances these competing priorities in the coming months.

The UK Treasury has decided to prevent ministers from tapping into emergency reserves to finance pay increases for public-sector workers. This move is significant as it highlights the government's stance on fiscal responsibility amidst rising demands for better wages in the public sector. With many workers feeling the pinch from inflation and cost-of-living increases, this decision could lead to further unrest and dissatisfaction among public employees.

Eli Lilly is positioned for significant growth as the obesity market expands, according to a recent SWOT analysis. The company's innovative approaches and strong market presence are likely to capitalize on the increasing demand for obesity treatments. This is important not only for investors looking for promising stocks but also for the healthcare sector, as it highlights the potential for new solutions to a growing health crisis.

The CFO of Oric Pharma has sold shares worth $159,718, which is a notable transaction in the company's financial landscape. Such sales can indicate various strategic moves or personal financial decisions, and they often attract attention from investors and analysts. Understanding the context behind these sales can provide insights into the company's future direction and the CFO's confidence in its performance.

Lululemon is facing significant challenges as its stock encounters headwinds due to slowing growth in the US market and the impact of tariffs. This situation is crucial as it highlights the brand's struggle to maintain its momentum in a competitive retail landscape, raising concerns among investors about future profitability and market share.

The U.S. Securities and Exchange Commission is reportedly investigating MassMutual regarding its accounting practices, as reported by the Wall Street Journal. This scrutiny raises concerns about the company's financial transparency and could impact investor confidence. Such investigations can lead to significant regulatory changes and affect the broader insurance industry, making it a critical issue for stakeholders.